Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia.

Moschiano E, Raca G, Fu C, Pattengale PK, Oberley MJ.

Leuk Res Rep. 2016 Aug 2;6:29-32. doi: 10.1016/j.lrr.2016.07.002. eCollection 2016.

3.

Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant.

Acree SC, Tovar JP, Pattengale PK, Wang LL, Church JA, Gaynon PS, Cassarino DS.

Fetal Pediatr Pathol. 2013 Jun;32(3):175-83. doi: 10.3109/15513815.2012.701264. Epub 2012 Oct 23.

PMID:
23092204
4.

BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.

Hemmeryckx B, Reichert A, Watanabe M, Kaartinen V, de Jong R, Pattengale PK, Groffen J, Heisterkamp N.

Oncogene. 2002 May 9;21(20):3225-31.

5.

Bethesda proposals for classification of lymphoid neoplasms in mice.

Morse HC 3rd, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan SC, MacLennan IC, Pattengale PK, Ward JM; Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium.

Blood. 2002 Jul 1;100(1):246-58.

6.

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Hiai H, Jaffe ES, MacLennan IC, Pandolfi PP, Pattengale PK, Perkins AS, Simpson RM, Tuttle MS, Wong JF, Morse HC 3rd; Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium.

Blood. 2002 Jul 1;100(1):238-45.

7.
8.

The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.

Heisterkamp N, Voncken JW, Senadheera D, Hemmeryckx B, Gonzalez-Gomez I, Reichert A, Pattengale PK, Groffen J.

Int J Mol Med. 2001 Apr;7(4):351-7.

PMID:
11254872
9.

Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.

Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK, Gonzalez-Gomez I, Groffen J, Heisterkamp N.

Cancer Res. 2001 Feb 15;61(4):1398-405.

10.

Biological characterization of uncleavable plasma membrane-anchored human macrophage colony-stimulating factor.

Deng P, Wang YL, Shahbazian VL, Pattengale PK.

Biochem Biophys Res Commun. 2000 Sep 16;276(1):304-11.

PMID:
11006122
11.

Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.

Heisterkamp N, Voncken JW, Senadheera D, Gonzalez-Gomez I, Reichert A, Haataja L, Reinikainen A, Pattengale PK, Groffen J.

Blood. 2000 Sep 15;96(6):2226-32.

13.

Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors.

Crooks GM, Fuller J, Petersen D, Izadi P, Malik P, Pattengale PK, Kohn DB, Gasson JC.

Blood. 1999 Jul 15;94(2):519-28.

14.

Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma.

Kundu RK, Sangiorgi F, Wu LY, Pattengale PK, Hinton DR, Gill PS, Maxson R.

Blood. 1999 Jul 1;94(1):275-82.

15.
16.

Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.

Brown MP, Topham DJ, Sangster MY, Zhao J, Flynn KJ, Surman SL, Woodland DL, Doherty PC, Farr AG, Pattengale PK, Brenner MK.

Nat Med. 1998 Nov;4(11):1253-60.

PMID:
9809548
17.

Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor.

Stripecke R, Skelton DC, Gruber T, Afar D, Pattengale PK, Witte ON, Kohn DB.

Hum Gene Ther. 1998 Sep 20;9(14):2049-62.

PMID:
9759932
18.

Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.

Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW.

Blood. 1997 Oct 15;90(8):2901-10.

19.

Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.

Pattengale PK.

Am J Pathol. 1997 Sep;151(3):647-9. No abstract available.

20.

The role of individual cysteine residues in the processing, structure, and function of human macrophage colony-stimulating factor.

Deng P, Wang YL, Pattengale PK, Rettenmier CW.

Biochem Biophys Res Commun. 1996 Nov 12;228(2):557-66.

PMID:
8920951
21.

Structural requirements for the ectodomain cleavage of human cell surface macrophage colony-stimulating factor.

Deng P, Rettenmier CW, Pattengale PK.

J Biol Chem. 1996 Jul 5;271(27):16338-43.

22.

BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N.

Blood. 1995 Dec 15;86(12):4603-11.

23.

Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China.

Bundy LM, Ru M, Zheng BF, Cheng L, Pattengale PK, Portis JL, Fan H.

Virology. 1995 Oct 1;212(2):367-82.

25.

Tumours of the lymphohaematopoietic system.

Pattengale PK.

IARC Sci Publ. 1994;(111):651-70. Review. No abstract available.

PMID:
8082924
26.

Establishment and characterization of a human mixed-lineage, T-lymphoid/myeloid cell line (USP-91).

Umiel T, Rettenmier CW, Siegel S, Ota S, Shimada H, Tran TW, Pattengale PK.

Blood. 1993 Sep 15;82(6):1829-37.

27.
29.

Multiple tumor types appear in a transgenic mouse with the ras oncogene.

Cardiff RD, Leder A, Kuo A, Pattengale PK, Leder P.

Am J Pathol. 1993 Apr;142(4):1199-207.

30.

Restricted oncogenicity of BCR/ABL p190 in transgenic mice.

Voncken JW, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Groffen J.

Cancer Res. 1992 Aug 15;52(16):4534-9.

31.

Human bcr-abl gene has a lethal effect on embryogenesis.

Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Groffen J.

Transgenic Res. 1991 Dec;1(1):45-53.

PMID:
1726940
33.
35.

Acute leukaemia in bcr/abl transgenic mice.

Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J.

Nature. 1990 Mar 15;344(6263):251-3.

PMID:
2179728
36.

Immunogenetic analysis of bone marrow aspirates in patients with non-Hodgkin lymphomas.

Ellison DJ, Hu E, Zovich D, Pinter-Brown L, Pattengale PK.

Am J Hematol. 1990 Mar;33(3):160-6.

PMID:
2154093
37.
38.

Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes.

Pattengale PK, Stewart TA, Leder A, Sinn E, Muller W, Tepler I, Schmidt E, Leder P.

Am J Pathol. 1989 Jul;135(1):39-61. Review.

39.

Murine interleukin-4 displays potent anti-tumor activity in vivo.

Tepper RI, Pattengale PK, Leder P.

Cell. 1989 May 5;57(3):503-12.

PMID:
2785856
40.

Differentiation in vitro of a leukemia virus-induced B-cell lymphoma into macrophages.

Hanecak R, Zovich DC, Pattengale PK, Fan H.

Mol Cell Biol. 1989 May;9(5):2264-8.

41.

A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.

Nussenzweig MC, Schmidt EV, Shaw AC, Sinn E, Campos-Torres J, Mathey-Prevot B, Pattengale PK, Leder P.

Nature. 1988 Dec 1;336(6198):446-50.

PMID:
3143076
43.
45.

Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model.

Schmidt EV, Pattengale PK, Weir L, Leder P.

Proc Natl Acad Sci U S A. 1988 Aug;85(16):6047-51.

46.

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P.

Cell. 1988 Jul 1;54(1):105-15.

PMID:
2898299
49.

Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.

Fujimiya Y, Chang WC, Bakke A, Horwitz D, Pattengale PK.

Cancer Immunol Immunother. 1987;24(3):213-20.

PMID:
3496152
50.

T-lymphocyte clones from leprosy skin lesions.

Modlin RL, Gersuk GM, Nelson EE, Pattengale PK, Gunter JR, Chen L, Cooper CL, Bloom BR, Rea TH.

Lepr Rev. 1986 Dec;57 Suppl 2:143-7. No abstract available.

PMID:
2952855

Supplemental Content

Loading ...
Support Center